38692-78-3

Upstream product

• 27387-23-1 5-methoxy-2-bromophenylacetonitrile 
• 19614-12-1 2-bromo-5-methoxybenzyl bromide 
• 86826-93-9 2-(2-bromo-5-methoxyphenyl)acetic acid 
• 51506-70-8 (2-bromo-5-hydroxy-phenyl)-acetonitrile 

Downstream Products

• 1069115-25-8 methyl 2-(2-bromo-5-hydroxy-phenyl)acetate 
• 1233354-71-6 C₁₇H₁₈BrNO₃ 
• 156945-58-3 <3-(allyloxy)phenyl>acetic acid 

Relevant academic research and scientific papers

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.